Therapeutic angiogenesis inhibitors in the treatment of cancer

Advances in Internal Medicine

Volumn 47, Issue , 2001, Pages 159-190

  Hidalgo, Manuel ^a,b   Scott Pierson, A ^a,b   Holden, Scott N ^b   Bergen, Michael ^b   Eckhardt, S Gail ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; 2-METHOXYESTRADIOL; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; COLLAGEN; DRUG DERIVATIVE; ENDOSTATIN; ENDOTHELIAL CELL GROWTH FACTOR; ENZYME INHIBITOR; ESTRADIOL; HYDROXAMIC ACID; LYMPHOKINE; MARIMASTAT; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY; ORGANIC COMPOUND; PEPTIDE FRAGMENT; PRINOMASTAT; PROTEIN TYROSINE KINASE; THALIDOMIDE; VASCULOTROPIN; VASCULOTROPIN A;

DRUG ANTAGONISM; HUMAN; IMMUNOLOGY; NEOPLASM; REVIEW;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLLAGEN; ENDOSTATINS; ENDOTHELIAL GROWTH FACTORS; ENZYME INHIBITORS; ESTRADIOL; HUMANS; HYDROXAMIC ACIDS; LYMPHOKINES; MATRIX METALLOPROTEINASES; NEOPLASMS; ORGANIC CHEMICALS; PEPTIDE FRAGMENTS; PROTEIN-TYROSINE KINASES; THALIDOMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035748883     PISSN: 00652822     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (193)

1. Folkman J: Tumor angiogenesis: Therapeutic applications. N Engl J Med 285:82-86, 1971.
2. Folkman J: Tumor angiogenesis, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, Lippincott-Raven, 1997, pp 3075-3085.
3. Bergers G, Javaherian K, Kin-Ming L, et al: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284:808-812, 1999.
4. Chambers AF, Matrisian L: Changing views of the role of matrix metalloproteinases in metastasis. / Natl Cancer Inst 89:1260-1270, 1997.
5. Kahari VM, Saarialho-Kere U: Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 31:34-45, 1999.
6. Ray JM, Stetler-Stevenson WG: Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO J 14:908-917, 1995.
7. Kleiner DE, Stetler-Stevenson WG: Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 43:S42-S51, 1999.
8. Denis LJ, Verweij J: Matrix metalloproteinase inhibitors: Present achievements and future prospects. Invest New Drugs 15:175-185, 1997.
9. Fini ME, Cook JR, Mohan R, et al: Regulation of matrix metalloproteinase gene expression, in Parks W, Mechan R (eds): Matrix Metalloproteinases. San Diego, Academic Press, 1998, pp 300-356.
10. Shapiro SD: Matrix metalloproteinase degradation of extracellular matrix: Biological consequences. Curr Opin Cell Biol 10:602-608,1998.
11. Kurogi T, Nabeshima K, Kataoka H, et al: Stimulation of gelatinase B and tissue inhibitors of metalloproteinase (TIMP) production in coculture of human osteosarcoma cells and human fibroblasts: Gelatinase B production was stimulated via upregulation of fibroblast growth factor (FGF) receptor. Int J Cancer 66:82-90, 1996.
12. Kondapaka SB, Fridman R, Reddy KB: Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int J Cancer 70:722-726, 1997.
13. Nuovo GJ: In situ detection of PCR-amplified metalloproteinase cDNAs, their inhibitors and human papillomavirus transcripts in cervical carcinoma cell lines. Int J Cancer 71:1056-1060, 1997.
14. Panek RL, Lu GH, Klutchko SR, et al: In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. / Pharmacol Exp Ther 283: 1433-1444, 1997.
15. Mira E, Manes S, Lacalle RA, et al: Insulin-like growth factor I-triggered cell migration and invasion are mediated by matrix metalloproteinase-9. Endocrinology 140:1657-1664, 1999.
16. Rosenthal EL, Johnson TM, Allen ED, et al: Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells. Cancer Res 58:5221-5230, 1998.
17. Ellerbroek SM, Hudson LG, Stack MS: Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion. Int J Cancer 78:331-337, 1998.
18. Sundareshan P, Nagle RB, Bowden GT: EGF induces the expression of matrilysin in the human prostate adenocarcinoma cell line, LNCaP. Prostate 40:159-166, 1999.
19. Duivenvoorden WC, Hirte HW, Singh G: Transforming growth factor a acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells. Clin Exp Metastasis 17:2734, 1999.
20. Powel W, Knox J, Navre M, et al: Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res 53:417-422, 1993.
21. Bramhall SR: The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical application. Int J Pancreatol 21:1-12, 1997.
22. Zucker S, Hymowitz M, Conner C, et al: Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann N Y Acad Sei 878:212-227, 1999.
23. Dano K, Romer J, Nielsen B, et al: Cancer invasion and tissue remodeling-cooperation of protease systems and cell types. APMIS 107:120-127, 1999.
24. Johansonn N, Airola K, Grenman R, et al: Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 151:273-289, 1997.
25. Uria A, Stahle-Backdahl M, Seiki M, et al: Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal epithelial cell interactions. Cancer Res 57:4882-4888, 1997.
26. Heppner KJ, Matrisian LM, Jensen RA, et al: Expression of most matrix metalloproteinases family members in breast cancer represents a tumor-induced host response. Am J Pathol 149:273-282, 1996.
27. Airola K, Karonen T, Vaalamo M, et al: Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. Br J Cancer 80:733-743, 1999.
28. Ozdemir E, Kakehi Y, Okuno H, et al: Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas. / Urol 161:1359-1363, 1999.
29. Koop S, Khokha R, Schmidt EE, et al: Overexpression of metalloproteinase inhibitor in B16F10 melanoma cells does not affect extravasation but reduces tumor growth. Cancer Res 54:4791-4797, 1994.
30. Bramhall SR, Neoptolemos JP, Stamp GW, et al: Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. / Pathol 182:347-355, 1997.
31. Grignon DJ, Sakr W, Toth M, et al: High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res 56:1654-1659, 1996.
32. Betz M, Huxley P, Davies SJ, et al: 1.8-A crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate primedside inhibitor with a distinct selectivity profile. Eur J Biochem 247: 356-363, 1997.
33. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ: Matrix metalloproteinase inhibitors. Invest New Drugs 15:61-75, 1997.
34. Wojtowicz-Praga S, Torri J, Johnson M, et al: Phase I trial of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. / Clin Oncol 16:2150-2156, 1998.
35. Primrose J, Bleiberg H, Daniel F, et al: Marimastat in récurrent colorectal cancer: Exploratory evaluation of biological activity by measurement of carcinoembryonic antigen. Br J Cancer 79:509-514, 1999.
36. Rosemurgy A, Harris J, Langleben A, et al: Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Am J Clin Oncol 22:247-252, 1999.
37. Bourthe A, Eisenhauer E, Steward W, et al: Phase I-II study of marimastat (BB2516) in patients with metastatic melanomas. Proc Annu Meet Am Soc Clin Oncol 16:1775A, 1997.
38. Carmichael J, Lederman J, Woll PGT, et al: Phase IB study of concurrent administration of marimastat and gemcitabine in non-resectable pancreatic cancer. Proc Annu Meet Am Soc Clin Oncol 17:888A, 1998.
39. O'Reilly S, Mani S, Ratain M, et al: Schedules of 5-FU and the matrix metalloproteinase inhibitor marimastat (MAR): A phase I study. Proc Annu Meet Am Soc Clin Oncol 17:839A, 1998.
40. Adams M, Thomas H: A phase I study of the matrix metalloproteinase inhibitor, marimastat, administered concurrently with carboplatin, to patients with relapsed ovarian cancer. Proc Annu Meet Am Soc Clin Oncol 17:838A, 1998.
41. Anderson 1C, Supko J, Eder J, et al: Pilot pharmacokinetic study of marimastat (MAR) in combination with carboplatin (C)/Paclitaxel (T) in patients with metastatic or locally advanced inoperable non-small cell lung cancer (NSCLC). Proc Annu Meet Am Soc Clin Oncol 18:719A, 1999.
42. Steward WP: Marimastat (BB2516): Current status and development. Cancer Chemother Pharmacol 43:S56-S60, 1999.
43. Eisenberger M, Sinibaldi V, Laufer M, et al: Phase I/II pharmacokinetic evaluation of marimastat in patients with advanced prostate cancer (PC): Identification of the biological active dose. Proc Annu Meet Am Soc Clin Oncol 19:1321A, 2000.
44. Nemunaitis J, Poole C, Primrose J, et al: Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: Selection of a biological active and tolerable dose for long term studies. Clin Cancer Res 4:1101-1109, 1998.
45. Nelson AR, Fingleton BM, Rothenberg ML, et al: Matrix metalloproteinase: Biologic activity and clinical implications. / Clin Oncol 18:1135-1149, 2000.
46. Rosemurgy A, Buckels J, Charnley R: A randomized study comparing marimastat to gemcitabine as first line therapy in patients with non-resectable pancreatic cancer. ProcAnnu Meet Am Soc Clin Oncol 18:1005A, 1999.
47. Fielding J, Scholefield J, Stuart P, et al: A randomized double-blind placebo controlled study of marimastat in patients with inoperable gastric adenocarcinoma. Proc Anna Meet Am Soc Clin Oncol 19:929A, 2000.
48. Millar A, Brown P, Moore J, et al: Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br J Clin Pharmacol 45:21-26, 1998.
49. Shalinsky DR, Brekken J, Zou H, et al: Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sei 878:236-270, 1999.
50. Santos O, McDermott CD, Daniels R, et al: Rodent pharmacokinetics and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases. Clin Exp Metastasis 15:499-508, 1997.
51. Shalinsky DR, Brekken J, Zou H, et al: Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations. Invest New Drugs 16:303-313, 1998.
52. Shalinsky D, Brekken J, Zou H, et al: Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: Single agent and combination chemotherapy studies. Clin Cancer Res 5:1905-1917, 1999.
53. Hande K, Wilding G, Ripple G, et al: A phase I study of AG3340, a matrix metalloproteinase (MMP) inhibitor in patients having advanced cancer. Ann Oncol 9:279A, 1998.
54. Wilding G, Small E, Ripple G, et al: Phase I study of AG3340, a matrix metalloproteinase inhibitor in combination with mitoxantrone/prednisone in patients having advanced prostate cancer. Ann Oncol 9:280A, 1998.
55. D'Olimpo J, Hande K, Collier M, et al: Phase I study of the matrix metalloproteinase inhibitor AG3340 in combination with paclitaxel and carboplatin for the treatment of patients with advanced solid tumors. Proc Annu Meet Am Soc Clin Oncol 18:615A, 1998.
56. Ferrante K, Winograd B, Canetta R: Promising new developments in cancer chemotherapy. Cancer Chemother Pharmacol 43:861-568,1999.
57. Golub LM, Lee HM, Ryan ME, et al: Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 12:12-26, 1998.
58. Lokeshwar BL: MMP inhibition in prostate cancer. Ann N Y Acad Sei 878:271-289, 1999.
59. Fife RS, Rougraff BT, Proctor C, et al: Inhibition of proliferation and induction of apoptosis by doxycycline in cultured human osteosarcoma cells. / Lab Clin Med 130:530-534, 1997.
60. Seftor RE, Seftor EA, De Larco JE, et al: Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clin Exp Metastasis 16:217-225, 1998.
61. Greenwald RA, Golub LM, Ramamurthy NS, et al: In vitro sensitivity of the three mammalian collagenases to tetracycline inhibition: Relationship to bone and cartilage degradation. Bone 22:33-38, 1998.
62. Ryan ME, Ramamurthy S, Golub LM: Matrix metalloproteinases and their inhibition in periodontal treatment. Curr Opin Periodontol 3:85-96, 1996.
63. Rowinsky E, Eckhardt S, Rizzo J, et al: Protracted daily treatment with Col-3, an oral tetracycline analog, matrix metalloproteinase (MMP) inhibitor, is feasible: A phase I pharmacokinetic and biological study. Proc Annu Meet Am Soc Clin Oncol 19:700A, 2000.
64. Rudek M, Figg W, Dyer V, et al: A phase I clinical trial of oral Col-3, a matrix metalloproteinase inhibitor, administered daily in patients .with refractory metastatic cancer. Proc Annu Meet Am Assoc Cancer Res 41:3894A, 2000.
65. Ferrara N: Molecular and biological properties of vascular endothelial growth factor. / Mol Med 77:527-543, 1999.
66. Park JE, Keller GA, Ferrara N: The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 4:1317-1326, 1993.
67. Ryan HE, Poloni M, McNulty W, et al: Hypoxia-inducible factor-1 a is a positive factor in solid tumor growth. Cancer Res 60:4010-4015, 2000.
68. Millauer B, Wizigmann-Voos S, Schnuren H, et al: High affinity VEGF binding and developmental expression suggest FLK-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72:835-846, 1993.
69. Guo D, Jia Q, Song HY, et al: Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. / Biol Chem 270:6729-6733, 1995.
70. Waltenberger J, Claesson Welsh L, Siegbahn A, et al: Different signal transduction properties of KDR and Fltl, two receptors for vascular endothelial growth factor. J Biol Chem 269:26988-26995, 1994.
71. Kukk E, Lymboussaki A, Taira S, et al: VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 122:3829-3837, 1996.
72. Asano M, Yukita A, Suzuki H: Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor. Jpn J Cancer Res 90:93-100, 1999.
73. Kanai T, Konno H, Tanaka T, et al: Effect of a neutralizing anti-VEGF antibody on human colon cancer. Proc Annu Meet Am Assoc Cancer Res 38:1387A, 1997.
74. Kanai T, Konno H, Tanaka T, et al: Anti-tumor and anti-metastatic effects of human-vascular-endothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. IntJ Cancer 77:933-936, 1998.
75. Konno H, Arai T, Tanaka T, et al: Antitumor effect of a neutralizing antibody to vascular endothelial growth factor on liver metastasis of endocrine neoplasm. Jpn J Cancer Res 89:933-939, 1998.
76. Kamiya K, Konno H, Tanaka T, et al: Antitumor effect on human gastric cancer and induction of apoptosis by vascular endothelial growth factor neutralizing antibody. Jpn J Cancer Res 90:794-800, 1999.
77. Tanaka T, Konno H, Kanai T, et al: Prevention of hepatic métastases after primary resection by a neutralizing anti-vascular endothelial growth factor (anti-VEGF) antibody. Proc Annu Meet Am Assoc Cancer Res 38:1388A, 1997.
78. Burger AM, Hendriks HR, Tang T, et al: Enhanced antitumor activity of anti-VEGF antibody HuMV833 given in combination with gemcitabine in human pancreatic tumor xenografts. Clin Cancer Res 6:579A, 2000.
79. Gordon MS, Talpaz M, Margolin K, et al: Phase I trial of recombinant humanized monoclonal anti-vascular endothelial growth factor (antiVEGF MAb) in patients with metastatic cancer. Proc Annu Meet Am Soc Clin Oncol 17:809A, 1998.
80. Margolin K, Gordon MS, Talpaz M, et al: Phase Ib trial of intravenous recombinant humanized monoclonal antibody (MAb) to vascular endothelial growth factor (rhuMAb VEGF) in combination with chemotherapy (ChRx) in patients with advanced cancer (ÇA): Pharmacologie and long-term safety data. Proc Ann u Meet Am Soc Clin Oncol 18:1678A, 1999.
81. Reese D, Fröhlich M, Bok R, et al: A phase II trial of humanized monoclonal anti-vascular endothelial growth factor antibody (rhuMAb VEGF) in hormone-refractory prostate cancer (HRPC). Proc Annu Meet Am Soc Clin Oncol 18:1355A, 1999.
82. Rockwell P, Witte L, Hicklin D, et al: Antitumor activity of anti-flk-1 monoclonal antibodies. Proc Annu Meet Am Assoc Cancer Res 38: 1788A, 1997.
83. Prewett M, Huber J, Li Y, et al: Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59:5209-5218, 1999.
84. Witte L, Hicklin DJ, Zhu Z, et al: Monoclonal antibodies targeting the VEGF receptor-2 (Flkl/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev 17:155-161, 1998.
85. Fong TA, Shawver LK, Sun L, et al: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/ KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59:99-106, 1999.
86. Angelov L, Salhia B, Roncari L, et al: Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas. Cancer Res 59:5536-5541, 1999.
87. Shaheen RM, Davis DW, Liu W, et al: Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 59:54125416, 1999.
88. Rosen L, Mulay M, Mayers A, et al: Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies. Proc Annu Meet Am Soc Clin Oncol 18:618A, 1999.
89. Miles S, Arasteh K, Gill P, et al: A multicenter dose-escalating study of SU5416 in AIDS-related Kaposi's sarcoma. Proc Annu Meet Am Soc Clin Oncol 19:683A, 2000.
90. Rosen PJ, Amado R, Hecht JR, et al: A Phase I/II study of SU5416 in combination with 5-FU/leucovorin in patients with metastatic colorectal cancer. Proc Annu Meet Am Soc Clin Oncol 19:5D, 2000.
91. Wedge SR, Ogilvie D], Dukes M, et al: VEGF receptor tyrosine kinase inhibitors as potential anti-tumor targets. Proc Annu Meet Am Assoc Cancer Res 41:3610A, 2000.
92. Laird AD, Vajkoczy P, Shawver LK, et al: SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60:4152-4160, 2000.
93. Rosen L, Hannah A, Rosen P, et al: Phase I experience oral SU006668, a novel multiple receptor tyrosine kinase inhibitor in patients with advanced malignancies. Clin Cancer Res 6:581A, 2000
94. Parry TJ, Cushman C, Gallegos AM, et al: Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA. Nucleic Acids Res 27:25692577, 1999.
95. Pavco PA, Bouhana KS, Gallegos AM, et al: Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin Cancer Res 6:2094-2103, 2000.
96. Weng DE, Weiss P, Kellacky C, et al: A phase I/II study of repetitive dose Angiozyme, a ribozyme targeting the Flt-1 receptor for VEGF. Clin Cancer Res 6:267A, 2000.
97. Gottesman MM: How cancer cells evade chemotherapy: Sixteenth Hinda Rosenthal Foundation award (lecture). Cancer Res 53:747-754, 1993.
98. Gasparini G, Harris AL: Does improved control of tumor growth require an anti-cancer therapy targeting both neoplastic and intratumoral endothelial cells? Eur J Cancer 30:201-206, 1994.
99. Bailar JC, Gornink HL: Cancer undefeated. N EngI J Med 336:15691574, 1997.
100. Hanahan D, Bergers G, Bergsland E: Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105:1045-1047, 2000.
101. Kerbel RS, Viloria-Petit A, Klement G, et al: Accidental antiangiogenic drugs: Anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 36:1248-1257, 2000.
102. Kerbel RS: Tumor angiogenesis: Past, present, and the near future. Carcinogenesis 21:505-515, 2000.
103. Browder T, Butterneid CE, Kraling BM, et al: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drugresistant cancer. Cancer Res 60:1878-1886, 2000.
104. Klement G, Baruchel S, Rak J, et al: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. / Clin Invest 105:Rl5-R24, 2000.
105. Steiner R: Angiostatic activity of anticancer agents in the chick embryo chorioallantoic membrane (CHE-CAM) assay, in Steiner R, Langer R (eds): Angiogenesis. Key Principles-Science-Technology-Medicine. Basel, Switzerland, Birkhauser Verlag, 1992, pp 449-454.
106. Presta M, Rusnati M, Belleri M, et al: Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process. Cancer Res 59:2417-2424, 1999.
107. Yonekura K, Basaki Y, et al: UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin Cancer Res 5:2185-2191, 1999.
108. O'Leary JJ, Shapiro RL, et al: Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin Cancer Res 5:181-187, 1999.
109. lyer S, Chapin DJ, et al: Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res 58:4510-4514, 1998.
110. Chaplin DJ, Pettit GR, Hill S: Anti-vascular approaches to solid tumor therapy: Evaluation of combretastatin A4 phosphate. Anticancer Res 19:189-196, 1999.
111. Seidman AD, Hudis CA, Albane IJ, et al: Dose-dense therapy with weekly 1 hour paclitaxel infusions in the treatment of metastatic breast cancer. / Clin Oncol 16:3353-3361, 1998.
112. Abu-Rustum NR, Aghajanian C, Barakat RR, et al: Salvage weekly paclitaxel in recurrent ovarian cancer. Semin Oncol 24:62-67, 1997.
113. Loffler TM, Freund W, Lipke J, et al: Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: Results of a phase I/II trial. Semin Oncol 23:32-34, 1996.
114. Alvarez A, Mickiewicz E, Brosio C, et al: Weekly taxol in patients who had relapsed or remained stable with taxol in a 21 day schedule. Proc Annu Meet Am Soc Clin Oncol 17:726A, 1998.
115. Herbst RS, Tran HT, Madden TL, et al: Phase I study of the angiogenesis inhibitor TNP-70 in combination with paclitaxel in patients with solid tumors. Proc Annu Meet Am Soc Clin Oncol 20:707A, 2000.
116. Spicer LJ, Hammond JM: Catecholestrogens inhibit proliferation and DNA synthesis of porcine granulöse cells in vitro: Comparison with estradiol, 5 alpha-dihydrotestosterone, gonadotropins and catecholamines. Mol Cell Endocrinol 64:119-126, 1989.
117. Fotsis T, Zhang Y, Pepper MS, et al: The endogenous oestrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumour growth. Nature 17:237-239, 1994.
118. Klauber N, Parangi S, Flynn E, et al: Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 57:81-86, 1997.
119. Mukhopadhyay T, Roth JA: Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol. Oncogene 14:379-384, 1997.
120. NakagawaYaki Y, Ogane N, Inoki Y, et al: The endogenous estrogen metabolite 2-methoxyestradiol induces apoptotic neuronal cell death in vitro. Life Sei 58:1461-1467, 1996.
121. Banerjeel SK, Zoubine MN, Sarkar DK, et al: 2-Methoxyestradiol blocks estrogen-induced rat pituitary tumor growth and angiogenesis: Possible role of vascular endothelial growth factor. Anticancer Res 20:2641-2645, 2000.
122. Schumacher G, Kataoka M, Roth JA, et al: Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines. Clin Cancer Res 5:493-499, 1999.
123. Lin HL, Liu TY, Chau GY, et al: Comparison of 2-methoxyestradiolinduced, docetaxel-induced, and Paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species. Cancer 89:983-994, 2000.
124. Klauber N, Parangi S, Flynn E, et al: Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 57:81-86, 1997.
125. Kataoka M, Schumacher G, Cristiano RJ, et al: An agent that increases tumor suppressor-transgene product coupled with systemic transgene delivery inhibits growth of metastatic lung cancer in vivo. Cancer Res 58:4761-4765, 1999.
126. Kataoka M, Schumacher G, Roth JA, et al: 2-Methoxyestradiol inhibits multiple métastases of human non-small cell lung cancer in nude mice with combination of systemic adenovims-p53. Proc Annu Meet Am Assoc Cancer Res 39:2849A, 1998.
127. Reiser F, Way D, Berna M, et al: Inhibition of normal and expérimental angiotumor endothelial cell proliferation and cell cycle progression by 2-methoxyestradiol. Proc Soc Exp Biol Med 219:211-216, 1998.
128. Yue TL, Wang X, Louden CS, et al: 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhib-its angiogenesis: Possible role for stress-activated protein kinase signaling pathway and Fas expression. Mol Pharmacol 51:951-962, 1997.
129. Tsukamoto A, Kaneko Y, Yoshida T, et al: 2-Methoxyestradiol, an endogenous metabolite of estrogen, enhances apoptosis and betagalactosidase expression in vascular endothelial cells. Biochem Biophys Res Commun 248:9-12, 1998.
130. LaVallee TM, Hembrough WA, Papathanassiu A, et al: 2-Methoxyestradiol does not require p53 in endothelial cells. Proc Anna Meet Am Assoc Cancer Res 40:3029A, 1999.
131. Wang Z, Yang D, Mohanakrishan AK, et al: Synthesis of B-ring homologated estradiol analogues that modulate tubulin polymerization and microtubule stability. /Med Chem 43:2419-2429, 2000.
132. D'Amato RJ, Lin CM, Flynn E, et al: 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc NatI Acad Sei USA 91:39643968, 1994.
133. Cushman M, He HM, Katzenellenbogen JA, et al: Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicines binding site. JMed Chem 38:2041-2049, 1995.
134. Tsutsui T, Tamura Y, Hagiwara M, et al: Induction of mammalian cell transformation and genotoxicity by 2-methoxyestradiol, an endogenous metabolite of estrogen. Carcinogenesis 21:735-740, 2000.
135. Josefsson E, Tarkowski A: Suppression of type II collagen-induced arthritis by the endogenous estrogen metabolite 2-methoxyestradiol. Arthritis Rheum 40:154-163, 1997.
136. Martucci CP, Fishman J: Impact of continuously administered catechol estrogens on uterine growth and luteinizing hormone secretion. Endocrinology 105:1288-1292, 1979.
137. Liu D, Bachmann KA: An investigation of the relationship between estrogen, estrogen metabolites and blood cholesterol levels in ovariectomized rats. / Pharmacol Exp Ther 286:561-568, 1998.
138. Liehr JG, Fang WF, Sirbasku DA, et al: Carcinogenicity of catechol estrogens in Syrian hamsters. / Steroid Biochem 24:353-356, 1986.
139. McBride WG: Thalidomide and congenital abnormalities. Lancet 2:1358,1961.
140. Lenz W: Thalidomide and congenital abnormalities. Lancet 1:45,1962.
141. Stephens TD: Proposed mechanisms of action in thalidomide embryopathy. Teratology 38:229-239, 1988.
142. D'Amato RJ, Loughnan MS, Flynn E, et al: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sei USA 91:4082-4088, 1994.
143. Kenyon BM, Browne F, D'Amato RJ: Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 64:971-978, 1997.
144. Sauer H, Günther T, Hescheler J, et al: Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals. Am J Pathol 156:151-158, 2000.
145. Vacca A, Ribatti D, Roncali L, et al: Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 87:503-508, 1994.
146. Vacca A, Di Loreto M, Ribatti D, et al: Bone marrow of patients with active multiple myeloma: Angiogenesis and plasma cell adhesion molecules: LFA-1, VLA-4, LAM-1, and CD44. Am f Hematol 50:9-14, 1995.
147. Vacca A, Ribatti D, Roncali L, et al: Angiogenesis in B-cell lymphoproliferative diseases: Biological and clinical studies. LeukLymphoma 20:27-38, 1995.
148. Vacca A, Ribbatti D, Presta M, et al: Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93:3064-3073, 1999.
149. Perez-Atayde AR, Sallan SE, Tedrow U, et al: Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 150:815-820, 1997.
150. Rajkumar SV, Fonseca R, Witzig TE, et al: Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia 13:469-472, 1999.
151. Munshi N, Wilson CS, Penn J, et al: Angiogenesis in newly diagnosed multiple myeloma: Poor prognosis with increased microvessel density (MVD) in bone marrow biopsies. Blood 92:98A, 1998.
152. Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571, 1999.
153. Barlogie B: Thalidomide in the management of multiple myeloma: The Arkansas experience in > 300 patients with single agent and combined therapy. Proc Annu Meet Am Soc Clin Oncol 20:28A, 2000.
154. Baidas SM, Winer EP, Flemming GF, et al: Phase II evaluation of thalidomide in patients with metastatic breast cancer. / Clin Oncol 18:2710-2717, 2000.
155. Eisen T, Boshoff C, Mak I, et al: Continuous low dose of thalidomide: A phase II study in advanced melanoma, renal cell, ovarian, and breast cancer. Br J Cancer 82:812-817, 2000.
156. Minor D, Elias L: Thalidomide treatment of metastatic renal cell cancer. Proc Annu Meet Am Soc Clin Oncol 20:1384A, 2000.
157. Fine HA, Figg WD, Jaeckle K, et al: Phase II trial of the anti-angiogenic agent thalidomide in patients with recurrent high-grade gliomas. / Clin Oncol 18:708-715, 2000.
158. Marx GM, McCowatt S, Boyle F, et al: Phase II study of thalidomide as an anti-angiogenic agent in the treatment of recurrent glioblastoma multiforme (GBM). Proc Annu Meet Am Soc Clin Oncol 20:613A, 2000.
159. Sugarbaker E, Thornwaite J, Ketcham A: Inhibitory effect of a primary tumor on metastatsis, in Day S, Myers P, Stansly PG, et al (eds): Progress in Cancer Research and Therapy. New York, Raven Press, 1977, pp 227-240.
160. Koike A, Moore GE, Mendoza CB, et al: Heterologous, homologous, and autologous transplantation of human tumors. Cancer 16:1065.1071, 1963.
161. O'Reilly M, Holgren L, Shing Y, et al: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of métastases by a Lewis lung carcinoma. Cell 79:315-328, 1994.
162. O'Reilly M, Boehm T, Shing Y, et al: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285, 1997.
163. Sim BKL, O'Reilly M, Liang H, et al: A recombinant human angiostatin inhibits experimental primary and metastatic cancer. Cancer Res 57:1329-1334, 1997.
164. Mauceri HJ, Hanna N, Beckett MA, et al: Combined effects of angiostatin and ionizing radiation in antitumor therapy. Nature 394:287-291, 1998.
165. Ito H, Rovira I, Bloom M, et al: Endothelial progenitor cells as putative targets for angiostatin. Cancer Res 59:5875-5877, 1999.
166. Boehm T, Folkman J, Shing Y, et al: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404-407, 1997.
167. Black WR, Agner RC: Tumor regression after endostatin therapy. Nature 391:450, 1998.
168. Eder JP, Clark JW, Supko JG, et al: Recombinant endostatin demonstrates safety, linear pharmacokinetics and biological effects on tumor growth factors: Results of a phase I clinical study. Clin Cancer Res 6:258A, 2000.
169. Herbst R, Tran H, Hess T, et al: A phase I clinical trial of recombinant human endostatin (rHE) in patients with solid tumors: Pharmacokinetic, safety, and efficacy analysis. Clin Cancer Res 6:259A, 2000.
170. Thomas JP, Schiller J, Lee F, et al: A phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin. Clin Cancer Res 6:260A, 2000.
171. Moore KS, Wehrli S, Roder H, et al: Squalamine: An aminosterol antibiotic from the shark. Froc Natl Acad Sei USA 90:1354-1358, 1993.
172. Sills AK, Williams JI, Tyler BM, et al: Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Res 58:2784-2792, 1998.
173. Teicher B A, Williams JI, Takeuchi H, et al: Potential of the aminosterol, squalamine in combination therapy in the rat 13762 mammary carcinoma and the murine Lewis lung carcinoma. Anticancer Res 18:25672574, 1998.
174. Kalidas M, Hammond LA, Patnaik A, et al: A phase I and pharmacokinetic (PK) study of the angiogenesis inhibitor, squalamine lactate (MSI-1256F). Proc Annu Meet Am Soc Clin Oncol 19:698A, 2000.
175. Eliceiri BR, Cheresh DA: The role of av integrins during angiogenesis. Mol Med 4:741-750, 1998.
176. Filardo EJ, Deming SL, Cheresh DA: Regulation of cell migration by the beta subunit ectodomain of ctv3. / Cell Sei 109:1615-1622, 1996.
177. Sung V, Stubbs JT III, Fisher L, et al: Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the av3 and avs integrins. / Cell Physiol 176:482-494,1998.
178. Gouon V, Tucker GC, Kraus-Berthier L, et al: Up-regulated expression of the 3 integrin and the 92-kDa gelatinase in human HT-144 melanoma cell tumors grown in nude mice. Int J Cancer 68:650-662, 1996.
179. Tawil NJ, Gowri V, Djoneidi M, et al: Integrin c^j can promote adhesion and spreading of metastatic breast carcinoma cells on the lymph node stroma. Int J Cancer 66:703-710, 1996.
180. Yun Z, Smith TW, Menter DG, et al: Differential adhesion of metastatic RAW117 large-cell lymphoma cells under static or hydrodynamic conditions: Role of integrin av3. Clin Exp Metastasis 15:3-11, 1997.
181. Vailhe B, Ronot X, Tracqui P, et al: In vitro angiogenesis is modulated by the mechanical properties of fibrin gels and is related to av3 integrin localization. In Vitro Cell Dev Biol Anim 33:763-773, 1997.
182. Kageshita T, Hamby CV, Hirai S, et al: av3 expression on blood vessels and melanoma cells in primary lesions: Differential association with tumor progression and clinical prognosis. Cancer Immunol Immunother 49:314-318, 2000.
183. Gasparini G, Brooks PC, Biganzoli E, et al: Vascular integrin av3: A new prognostic indicator in breast cancer. Clin Cancer Res 4:26252634, 1998.
184. Natali PG, Hamby CV, Felding-Habermann B, et al: Clinical significance of av3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res 57:15541560, 1997.
185. Erdreich-Epstein A, Shimada H, Groshen S, et al: Integrins av3 and avs are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res 60:712-721, 2000.
186. Zheng DQ, Woodard AS, Fornaro M, et al: Prostatic carcinoma cell migration via av3 integrin modulated by a focal adhesion kinase pathway. Cancer Res 59:1655-1664, 1999.
187. Zhou Q, Sherwin RP, Parrish C, et al: Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix, inhibits breast cancer progression. Breast Cancer Res Treat 61:249-260, 2000.
188. Gutheil JC, Campbell TN, Pierce PR, et al: Phase I study of Vitaxin, an anti-angiogenic humanized monoclonal antibody to vascular integrin vs- Proc Annu Meet Am Soc Clin Oncol 17:832A, 1998.
189. Guthiel JC, Campbell TN, Pierce PR, et al: Targeted antiangiogenic therapy for cancer using Vitaxin: A humanized monoclonal antibody to the integrin av3. Clin Cancer Res 6:3056-3061, 2000.
190. Patel SR, Jenkins J, Papadopoulos NE, et al: A pilot study of an angiogenesis inhibitor Vitaxin in patients with advanced leiomyosarcomas. Proc Anna Meet Am Soc Clin Oncol 19:2202A, 2000.
191. Chatterjee S, Matsumura A, Schradermeier J, et al: Human malignant glioma therapy using anti-av3 integrin agents. / Neurooncol 46:135144, 2000.
192. Castel S, Pagan R, Garcia R, et al: av integrin antagonists induce the disassembly of focal contacts in melanoma cells. EUT J Cell Biol 79:502-512, 2000.
193. Eskens F, Dumez H, Verweij J, et al: Cilengitide (EMD 121974) inhibits angiogenesis by blocking av3 and otv5 integrins: Mature results of a phase I and pharmacological study. Clin Cancer Res 6:296A, 2000.